Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ)

CAPS Rating: 2 out of 5

A specialty pharmaceutical company, which focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Recs

0
Player Avatar jagad5 (< 20) Submitted: 7/15/2011 12:38:47 PM : Outperform Start Price: $36.95 JAZZ Score: +23.50

revenues are growing 60% per year but PE is only 31, implying <10% growth rate.

Next quarter expect:
REV - $66M
NET - $26M
EPS - $0.63
R^2 = 0.95
Fair value = $100+

Report this Post Reply

Featured Broker Partners


Advertisement